Don’t forget you can visit MyAlerts to manage your alerts at any time.
Delaware Business Court Insider
By Tom McParland | December 10, 2018
Vice Chancellor Tamika Montgomery-Reeves said Monday that Newark-based biotech firm iBio Inc. had filed its suit against Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung outside of the three-year statute of limitations.
1 minute read
By Tom McParland | December 10, 2018
Vice Chancellor Tamika Montgomery-Reeves said Monday that Newark-based biotech firm iBio Inc. had filed its suit against Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung outside of the three-year statute of limitations.
1 minute read
By Phillip Bantz | December 10, 2018
Oler will be primarily responsible for business development, investor relations and legal affairs. He'll be focused on forging relationships with global partners to help advance an Onconova cancer drug called Rigosertib.
1 minute read
By Tom McParland | December 7, 2018
Paul Weiss partner Lewis R. Clayton defended the ruling before all five justices of the state's high court, saying that Akorn had "collapsed" under the weight of its regulatory compliance problems after agreeing to the $34-per-share buyout in early 2017.
1 minute read
Delaware Business Court Insider
By Tom McParland | December 7, 2018
The Chancery Court's Oct. 1 decision was the first in the state to allow a potential buyer to escape its merger obligations based on a finding that one had occurred.
1 minute read
By Max Mitchell | December 6, 2018
A federal jury in Pennsylvania has hit Israel-based drugmaker Teva Pharmaceuticals with a more than $6.1 million verdict over claims that a manager discriminated against an American employee.
1 minute read
By Jenna Greene | December 6, 2018
The five Delaware Supreme Court justices did little to tip their hand, but the chief justice pressed Cravath's Daniel Slifkin hardest on his client Akorn's regulatory problems with the Food and Drug Administration.
1 minute read
Delaware Business Court Insider
By Tom McParland | December 5, 2018
An attorney for Fresenius SE & Co. on Wednesday defended a landmark Chancery Court ruling that allowed the German health care firm to walk away from its $4.3 billion deal to buy generic drugmaker Akorn Inc. based on a material adverse change in Akorn's business, saying the decision was well-rooted in evidence presented during an expedited trial.
1 minute read
By Michael H. Reed | December 5, 2018
Does the U.S. Supreme Court's decision in 'Bristol Myers Squibb' apply to class actions?
1 minute read
By Scott Graham | December 4, 2018
Hearing his first patent case, Brett Kavanaugh says legislators tried and failed to exclude private sales from a list of disqualifying prior art. Other justices sounded less sure.
1 minute read
Presented by BigVoodoo
The Daily Report is honoring those attorneys and judges who have made a remarkable difference in the legal profession.
Consulting Magazine identifies consultants that have the biggest impact on their clients, firms and the profession.
The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.
Health Law Associate CT Shipman is seeking an associate to join our national longstanding health law practice. Candidates must have t...
Shipman & Goodwin LLP is seeking two associates to expand our national commercial real estate lending practice. Candidates should have ...
Associate attorney position at NJ Immigration Law firm: Leschak & Associates, LLC, based in Freehold, NJ, is looking for a full time ass...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS